1st in Large Joints for CERASORB Ortho Foam
Elizabeth Hofheinz, M.P.H., M.Ed. • Thu, May 25th, 2017
CURASAN Inc., the U.S. subsidiary of curasan AG, has announced the first implantation of CERASORB Ortho Foam bone graft product, marking the debut on the U.S. orthopedic bone graft substitute market.
As the company wrote in its May 11, 2017 news release, “CERASORB Ortho Foam was used in a challenging knee arthrodesis case performed by Divakar Krishnareddy, M.D. at Los Angeles Community Hospital in Los Angeles, California.
“Globally, CURASAN has a strong 20 plus year history of delivering novel and highly effective materials for the bone regeneration market. With numerous patents, peer-reviewed clinical studies, and robust on-going research and development and clinical programs, we provide cost-effective and clinically proven orthobiologic solutions that integrate seamlessly in the operating room,” said company President M. Shane Ray. “We are excited to enter the orthopedic market here in the United States and look forward to working with our sales partners to provide advanced biomaterials to our surgeon customers throughout the USA”.
Dr. Krishnareddy commented to OTW, “It’s exciting to see a product that has both excellent handling and strong clinical evidence become available in the USA. CERASORB Ortho Foam’s handling is very easy to adapt to underlying anatomy, preventing large gaps while allowing graft placement where you need it.”